# Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma

> **NCT04051047** · EARLY_PHASE1 · WITHDRAWN · sponsor: **University of Michigan Rogel Cancer Center**

## Conditions studied

- Glial Tumor of Brain
- Diffuse Intrinsic Pontine Glioma
- Glioma

## Interventions

- **DRUG:** Gemcitabine
- **PROCEDURE:** Tumor biopsy and blood draw

## Key facts

- **NCT ID:** NCT04051047
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-11-30
- **Primary completion:** 2021-12
- **Final completion:** 2021-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn by Principal Investigator
- **Last updated:** 2019-11-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04051047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04051047, "Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04051047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*